The six antitrust class-action lawsuits that have been brought against AbbVie could result in more scrutiny of settlement agreements between the innovator and the biosimilar manufacturer, with potential antitrust complications.
US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.
Petitioners will continue to be able to launch litigation simultaneously before both the district court and the Patent Trial and Appeal Board, effectively having two bites at the apple, according to John Kirkland, director of IP at biopharmaceutical company Alkermes.
Eli Lilly has entered into a $35m global licensing and research agreement with biotech company Avidity Biosciences.
Enzo Life Sciences has entered into a settlement and licensing agreement with pharmaceutical companies Hologic and Grifols, ending a patent dispute between the parties.
Fresenius Kabi has submitted a petition for inter partes review of US patent number 9,856,287, a patent owned by Amgen.
Amgen subsidiary Immunex has appealed against a Patent Trial and Appeal Board decision which invalidated a patent claiming antibodies that target human interleukin-4 receptors.
Chinese companies have entered into a research agreement with scientists in the US and Canada to develop a therapy for neurological disorders by using the natural power of the immune system.
Duane Morris & Selvam has strengthened its IP practice with the addition of John Alison from Winston & Strawn.
Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.